AbbVie Reports Third-Quarter 2026 Financial Results

AbbVie (ABBV) reported Q3 2026 net revenues of $17.404B, up 10.3%. GAAP EPS was $2.37, adjusted EPS $3.82. Skyrizi and Rinvoq revenues grew 22.7% and 23.9% respectively. Humira revenues declined 31.2%. AbbVie raised 2026 adjusted EPS guidance to $13.95-$13.99 and announced a 5.2% dividend increase for 2027.

Original reporting
Published Oct 30, 2026, 11:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AbbVie Reports Third-Quarter 2026 Financial Results — source image
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The earnings beat and raised guidance are likely to drive short-term buying pressure, while the acquisition of Apogee Therapeutics adds long-term growth potential.

02

Market read

AbbVie's earnings and guidance raise are material for investors and can influence the broader healthcare sector.

03

What to watch

Acquisition integration risk and higher R&D spend could pressure margins.

Relevance 9/10Novelty 9/10Timing: pre-market today

Background

AbbVie released its third-quarter 2026 financial results, including revenue growth, EPS figures, and guidance updates.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie reported Q3 2026 earnings with revenue up 10.3% and raised full-year adjusted EPS guidance.

Expected impact

likely upside as market prices in higher guidance and dividend increase

Evidence & confidence

Higher guidance and a 5.2% dividend hike suggest improved profitability, supporting price appreciation.

Market effects

Positive earnings may lift the healthcare and pharma sector.

Boosts US market sentiment, especially large-cap biotech stocks.

Sets a positive tone for global pharma equities.

Counterpoint

If guidance raise is already priced in, the stock could face short-cover pullback.

Key entities

  • AbbVie

    US-listed biopharma company reporting Q3 results.

  • Apogee Therapeutics

    Acquired biotech expanding AbbVie's immunology pipeline.

Related articles

$ABBVMed

AbbVie to Invest More than $200 Million in Puerto Rico to Modernize Barceloneta Manufacturing Campus

AbbVie (NYSE: ABBV) plans to invest $217 million to modernize its biologics manufacturing campus in Puerto Rico, creating 100 new jobs. The project, part of a $100 billion U.S. investment commitment, will integrate AI and advanced technologies to support current and future immunology and neuroscience medications. The facility is expected to be operational by 2030.

$ABBVHighAI 9/10

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

AbbVie will pay up to $2.54 billion to develop cancer treatments with private German biotech Disco Pharmaceuticals, including a $40 million upfront fee and milestone payments. Disco will handle research, with AbbVie having exclusive licensing rights. The deal focuses on AND-gated bispecific therapeutics for solid tumors, with Disco aiming to select a candidate in late 2024.